Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects

A Randomized , Double Blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients With Early Stage Alzheimer's Disease

A Randomized, Double-blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients with Early Alzheimer's Disease

Study Overview

• Status: Completed
• Conditions: Alzheimer's Disease
• Intervention / Treatment: Drug: Placebo; Drug: BPN14770

• Study Type: Interventional
• Enrollment (Actual): 255
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Gilbert, Arizona, United States, 85296
      • Generations at Agritopia/CCT Research
  • California
    • Bellflower, California, United States, 90709
      • CiTrials, Inc.
    • Costa Mesa, California, United States, 92626
      • ATP Clinical Research, Inc
    • Long Beach, California, United States, 90807
      • Alliance for Research
    • San Diego, California, United States, 92103
      • Pacific Research Network Inc.
    • Santa Ana, California, United States, 92704
      • HB Clinical Trials, Inc.
  • Colorado
    • Denver, Colorado, United States, 80218
      • Mile High Research Center
  • Florida
    • Atlantis, Florida, United States, 33462
      • JEM Research Insitute
    • Coral Gables, Florida, United States, 33134
      • Linfritz Research Group
    • Delray Beach, Florida, United States, 33445
      • Brain Matters Research
    • Hallandale Beach, Florida, United States, 33009
      • MD Clinical
    • Hialeah, Florida, United States, 33016
      • Galiz Research
    • Lake Worth, Florida, United States, 33449
      • Alzheimer's Research and Treatement Center
    • Miami, Florida, United States, 33126
      • Pharmax Research Clinic
    • Miami, Florida, United States, 33126
      • BioMed Research Institute
    • Miami, Florida, United States, 33126
      • Finlay Medical Research
    • Miami, Florida, United States, 33135
      • Vitae Research Center, LLC
    • Miami, Florida, United States, 33176
      • Advanced Clinical Research Network
    • Miami, Florida, United States, 33125
      • Optimus Clinical Research
    • Miami, Florida, United States, 33145
      • Arocha Research Center
    • Miami, Florida, United States, 33155
      • Allied Biomedical Research Institute Inc.
    • Orlando, Florida, United States, 32807
      • Gutierrez Medical Center LLD
    • Ormond Beach, Florida, United States, 32174
      • Neurology Associates of Ormond Beach
    • Palm Beach, Florida, United States, 33410
      • Palm Beach Neurological Center
    • Palmetto Bay, Florida, United States, 33157
      • IMIC Inc
    • Pensacola, Florida, United States, 32514
      • Synergy Clinical Research
    • Pompano Beach, Florida, United States, 33064
      • Quantum Laboratories
  • Illinois
    • Elk Grove Village, Illinois, United States, 60007
      • Neurosciences Research
  • New Jersey
    • Berlin, New Jersey, United States, 08009
      • Hassman Research Institute
    • Toms River, New Jersey, United States, 08755
      • Advanced Memory Research Institute of NJ PC
  • New York
    • Brooklyn, New York, United States, 11229
      • Integrative Clinical Trials
    • Lake Success, New York, United States, 11042
      • Neurological Associates of Long Island
    • New York, New York, United States, 10036
      • Manhattan Behavioral Medicine PLLC
  • North Carolina
    • Charlotte, North Carolina, United States, 28270
      • Alzheimers Memory Center
  • Ohio
    • Dayton, Ohio, United States, 45459
      • Neurology Diagnostics, Inc.
    • Westerville, Ohio, United States, 43081
      • MDH Research
  • Oregon
    • Portland, Oregon, United States, 97210
      • Summit Research Network
  • Pennsylvania
    • Allentown, Pennsylvania, United States, 18104
      • Lehigh Center for Clinical Research
  • Tennessee
    • Cordova, Tennessee, United States, 38018
      • Neurology Clinic, P.C.
  • Utah
    • Orem, Utah, United States, 84058
      • Aspen Clinical Research
    • Salt Lake City, Utah, United States, 84107
      • Wasatch Clinical Research, LLC

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 55 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Males or females between the ages of 55 and 85 years with a clinical diagnosis of early stage AD, defined according to the following criteria assessed during Screening and at Baseline :

   1. Clinical Dementia Rating (CDR) score of 0.5 or 1, with Memory Box score of 0.5 or greater
   2. MMSE score of 20 or greater
   3. RBANS DMI score ≤ 85 Note: PET imaging for amyloid is not required for diagnosis, which will be made on clinical grounds.

2. Currently receiving a stable (at least 2 months) dose regimen of donepezil or another cholinesterase inhibitor for treatment of Alzheimer's disease. Doses of these drugs may not be changed during the trial.

   Note: Memantine is not permitted during the trial and must be discontinued at least 3 weeks prior to Baseline.

3. Modified Hachinski Ischemia score < 4.
4. Body mass index (BMI) < 38 kg/m2, inclusive, and body weight of >48 kg (105 pounds) at screening.
5. Female subjects must be at least two years post-menopausal (subjected reported menopausal status), surgically sterile (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least 6 months prior to first study drug administration), or willing to either (1) utilize hormonal contraception plus one barrier method or (2) use two barrier methods of contraception (e.g. diaphragm and spermicide) from initial screening until one month after taking the final dose. An intrauterine device (IUD) is considered a barrier method of contraception in this study. Male subjects must be willing to inform female partners of their participation in the study and must agree to use adequate contraceptive methods (vasectomy performed at least 6 months prior to first study drug administration, or use at least one barrier method of birth control).
6. Able to understand and comply with the study procedures, voluntarily agree to participate in this study, and provide written informed consent prior to start of any study-specific procedures.
7. All subjects must have a caregiver who is willing and able to ensure compliance with study medications, visits, and study procedures.

Exclusion Criteria:

1. Any medical or neurological condition (other than early stage AD) that might be a contributing cause to the subject's cognitive impairment.
2. History of stroke or multiple (>3 discreet episodes) Transient Ischemic Attacks (TIAs), severe head trauma with cognitive sequelae, uncontrolled seizures, or unexplained prolonged loss of consciousness (> 1 minute) during the past year.
3. Clinically significant major psychiatric illness during the past 6 months.
4. History of unstable angina, myocardial infarction, chronic heart failure, or clinically significant conduction abnormalities during the past year.
5. Clinically significant liver or renal disease.
6. Clinically significant abnormality, in the Investigator's judgment, in hematology, chemistry, or urinalysis.
7. Positive serology results for hepatitis B surface antigen (HbsAg) or hepatitis C virus (HCV).

8. Abnormal liver function test at the Screening Visit (aspartate aminotransferase or alanine aminotransferase >2

   × the upper limit of normal [ULN], or total bilirubin >1.7 × ULN, based on appropriate age and gender normal values). Subjects may be re-screened once.

9. Marked hypotension (systolic blood pressure [BP] ˂90 mmHg or diastolic BP ˂50 mmHg) or hypertension (systolic BP ˃160 mmHg or diastolic BP ˃100 mmHg) based on sitting values. O ut-of-range results may be repeated once at Screening, and eligibility must be confirmed at Baseline.
10. Marked bradycardia (heart rate ˂45 beats per minute [bpm]) or tachycardia (heart rate ˃115 bpm) based on supine ECG values. Out-of-range results may be repeated once at Screening, and eligibility must be confirmed at Baseline.
11. Clinically important conduction abnormalities on ECG, or evidence or history of long QT syndrome based on supine ECG values obtained at Screening. Out-of-range results may be repeated once and eligibility confirmed at Baseline.
12. Active gastric or duodenal ulcers or other diseases of the gastrointestinal tract that could interfere with absorption of study drug. Note: Subjects with a history of appendectomy or cholecystectomy may be enrolled.
13. Active acute or chronic infectious diseases that would interfere with subject's participation in the study.
14. Unable to discontinue centrally active medications (other than cholinesterase inhibitors), including memantine, psychotropic drugs other than SSRIs (which must have been stable for 2 months and remain stable throughout the study), sedative antihistamines or other centrally active medications with potential cognitive effects (e.g., CNS-penetrant beta blockers).
15. Unable to discontinue moderate to strong inhibitors or inducers of CYP3A4, CYP2D6, or other cytochromes at least 14 days prior to the first dose of study drug. A complete listing of such inhibitors or inducers may be found in http://medicine.iupui.edu/clinpharm/ddis/main-table (Other prescription or non-prescription drugs such as antihypertensive or cholesterol lowering agents are allowed, if, in the Investigator's judgement, they would not interfere with the study medication or the cognitive testing.)
16. A suicidal ideation intensity score of 3 or higher per screening Columbia Suicide Severity Rating Scale (CSSRS) assessment on Day 1 (Baseline) and/or any suicidal behavior within the past 28 days.
17. History of chronic alcohol or other substance abuse, including marijuana, within the previous year prior to the Screening visit (per the current edition of the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition: DSM-5), or regular (daily) consumption of alcohol exceeding two bottles of beer, or the equivalent amount of other forms of alcohol (1 serving = 12 oz beer, 5.0 oz wine, or 1.5 oz distilled spirits).
18. Inability or unwillingness to comply with the protocol, including performing the cognitive function tests, or likely inability to complete the study.
19. Participation in other clinical studies involving investigational drug within the previous 30 days prior to the Screening Visit.
20. Donation of blood within 4 weeks, or blood products within 2 weeks, prior to first study drug administration.
21. History of clinically significant drug allergy that includes symptoms such as shortness of breath, rash, or edema.
22. Clinically significant B12 deficiency within 12 months prior to Visit 1 (Screening). Participants on stable replacement therapy for a minimum of 3 consecutive months immediately prior to Visit 1 (Screening) may be included

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Drug: Placebo; Placebo
Experimental: BPN14770 10mg bid; 10 mg bid dose of the Drug BPN14770	Drug: BPN14770; Drug BPN14770
Experimental: BPN 14770 25mg bid; 25mg bid dose of the Drug BPN14770	Drug: BPN14770; Drug BPN14770

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Repeatable Battery for the Assessment of Neurological Status- Delayed Memory Index (RBANS- DMI) at Week 13	The RBANS is a brief, individually administered test measuring attention, language, visuospatial/constructional abilities, and immediate and delayed memory. It consists of 12 subtests, which yield 5 Index scores and a Total Scale score. Lower scores indicate worse performance on the test (and thus greater impairment). Scores for the RBANS DMI range from 40 (greater impairment) to 160 (improved function), with higher scores indicating improved function.	Baseline, Week 13

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Repeatable Battery for the Assessment of Neurological Status (RBANS) Total Score at Week 13	The RBANS is a brief, individually administered test measuring attention, language, visuospatial/constructional abilities, and immediate and delayed memory. It consists of 12 subtests, which yield 5 Index scores and a Total Scale score. Lower scores indicate worse performance on the test (and thus greater impairment). The RBANS total score ranges from 40 to 160, with higher scores indicating improved function.	Baseline, Week 13
Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) Total Score at Week 13	The ADCS-ADL is an interviewer-administered informant-based scale where the informant (caregiver) responds to 23 activities of daily living questions about the participant. The questions range from basic to instrumental activities of daily living. The total score ranges from 0-78 and a higher score signifies greater functional ability.	Baseline, Week 13
Change From Baseline in Mini-Mental State Exam (MMSE) Total Score at Week 13	The MMSE consists of 11 items covering orientation, memory (recent and immediate), concentration, language and praxis. Total score ranges from 0 (severe cognitive impairment) to 30 (intact cognitive function), with lower scores indicating greater cognitive impairment. In participants with a diagnosis of AD, lower scores indicating worse disease. A score of 20 to 24 suggests mild dementia, 13 to 20 suggests moderate dementia, and less than 12 indicates severe dementia.	Baseline, Week 13
Change From Baseline in Clinical Dementia Rating Sum of Boxes Score (CDR-SB) at Week 13	The CDR was developed primarily to assess severity level in persons with dementia. Six domains were assessed and then synthesized to assign a Global CDR score. The domains were memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Impairment was defined only when caused by cognitive loss rather than by physical disability or other non-cognitive factors. CDR is an ordinal parameter (scale 0 [least impairment]-3 [severe impairment]). CDR-SB score was obtained by summing each of the domain box scores, with scores ranging from 0 (least impairment) to 18 (severe impairment).	Baseline, Week 13
Clinical Global Impression - Improvement (CGI-I) Score	The CGI-I employs a 7-point Likert scale to measure the overall improvement in the participant's condition post-treatment. The Investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. Response choices included: 0=not assessed, 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse.	Week 13

Collaborators and Investigators

• Sponsor: Tetra Discovery Partners
• Investigators: Study Director: Scott Reines, MD, Tetra Discovery Partners

Study record dates

Study Major Dates

• Study Start (Actual): April 30, 2019
• Primary Completion (Actual): February 4, 2020
• Study Completion (Actual): February 4, 2020

Study Registration Dates

• First Submitted: January 18, 2019
• First Submitted That Met QC Criteria: January 23, 2019
• First Posted (Actual): January 25, 2019

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: January 30, 2025
• Last Verified: January 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Mental Disorders; Neurocognitive Disorders; Dementia; Tauopathies; Neurodegenerative Diseases; Alzheimer Disease; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Phosphodiesterase Inhibitors; Phosphodiesterase 4 Inhibitors; BPN14770
• Other Study ID Numbers: BPN14770-CNS-201

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No